Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study

Miriam Estébanez, German Ramírez-Olivencia, Tatiana Mata, David Martí, Carlos Gutierrez, Begoña de Dios, María Dolores Herrero, Ana Roel, Yolanda Martínez, Alejandro Aguirre, Francisco Alcántara-Nicolás, Pablo Fernández-González, Elena López, Lucía Elena Ballester, María Mateo-Maestre, Sergio Campos, María Jesús Sánchez-Carrillo, Antonio Fe, Francisco Javier Membrillo de Novales, COVID 19 CENTRAL DEFENSE HOSPITAL “GÓMEZ ULLA” TEAM
doi: https://doi.org/10.1101/2020.05.15.20084293
Miriam Estébanez
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mestmun@mde.es
German Ramírez-Olivencia
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana Mata
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Martí
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Gutierrez
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Begoña de Dios
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Dolores Herrero
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Roel
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yolanda Martínez
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
Roles: Nurse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro Aguirre
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Alcántara-Nicolás
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo Fernández-González
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena López
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucía Elena Ballester
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Mateo-Maestre
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Campos
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Jesús Sánchez-Carrillo
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Fe
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Javier Membrillo de Novales
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
1Central Defense Hospital “Gómez Ulla”, Glorieta Ejército, 1, 28047 Madrid (Spain), Telephone: 914 22 20 00
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background COVID-19 pneumonia is associated with significant mortality and has no approved antiviral therapy. Interferon beta1 has shown in vitro studies a potent inhibition of SARS-CoV and MERS-CoV. In an in vitro study, SARS-CoV-2 had more sensitivity to IFN-I pretreatment that SARS-CoV. A combination of IFN beta1b administered subcutaneously with other antiviral treatments has been recommended in several guidelines. However, clinical trial results for the treatment of COVID-19 are pending. We aimed to assess the efficiency of IFN beta1b in COVID19 comparing the in-hospital mortality between patients who received IFN beta1b and patients did not receive.

Methods In this retrospective cohort study, we included hospitalized adults with COVID-19 between February 23th and April 4th, 2020, at the Central Defense Hospital (Madrid, Spain). Subcutaneous interferon beta-1b was recommended in moderate-severe pneumonia. The primary endpoint was in-hospital mortality. Univariate and multivariate analysis was performed to identify variables associated with in-hospital mortality.

Findings We analyzed 256 patients (106 patients in interferon group and 150 patients in control group). At admission, patients who did not receive interferon beta1b presented a greater number of comorbidities. The overall mortality rate was 24.6% (63/256). Twenty-two patients (20.8%) in the interferon group died and 41 (27.3%) in the control group (p=0.229). In the multivariate analysis, the predictors of in-hospital mortality were age, severity of clinical picture at admission and hydroxychloroquine treatment.

Interpretation In hospitalized patients with COVID-19, interferon beta1b treatment was not associated to decrease in-hospital mortality. Further assessment of the earlier administration of this drug in randomized trials is recommended.

Funding none.

Evidence before this study We searched Pubmed on April 27th, 2020, for articles evaluating the efficacy of interferon beta in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), using the terms: “interferon beta and (COVID-19 or SARS-CoV-2)”. We only found 5 articles. Of them, there was only one original article in English, which was a descriptive study of a case series with solid organ transplant from Spain.

Added value of this study This is the first article that reports the efficacy of interferon beta1b in the treatment of patients with COVID-19. We compared the in-hospital mortality between patients who received interferon beta1b and patients who did not. Patients in both groups received other drugs with a potential antiviral and immunomodulatory effect. There was no significant difference in in-hospital mortality between both groups.

Implications of all the available evidence In our retrospective cohort, treatment with interferon beta1b had not impact on in-hospital survival, however it would be of clinical interest to evaluate the effect of early administration of this drug in the control of SARS-CoV-2 infection in larger randomized clinical trials.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funded

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

NA

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 21, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study
Miriam Estébanez, German Ramírez-Olivencia, Tatiana Mata, David Martí, Carlos Gutierrez, Begoña de Dios, María Dolores Herrero, Ana Roel, Yolanda Martínez, Alejandro Aguirre, Francisco Alcántara-Nicolás, Pablo Fernández-González, Elena López, Lucía Elena Ballester, María Mateo-Maestre, Sergio Campos, María Jesús Sánchez-Carrillo, Antonio Fe, Francisco Javier Membrillo de Novales, COVID 19 CENTRAL DEFENSE HOSPITAL “GÓMEZ ULLA” TEAM
medRxiv 2020.05.15.20084293; doi: https://doi.org/10.1101/2020.05.15.20084293
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study
Miriam Estébanez, German Ramírez-Olivencia, Tatiana Mata, David Martí, Carlos Gutierrez, Begoña de Dios, María Dolores Herrero, Ana Roel, Yolanda Martínez, Alejandro Aguirre, Francisco Alcántara-Nicolás, Pablo Fernández-González, Elena López, Lucía Elena Ballester, María Mateo-Maestre, Sergio Campos, María Jesús Sánchez-Carrillo, Antonio Fe, Francisco Javier Membrillo de Novales, COVID 19 CENTRAL DEFENSE HOSPITAL “GÓMEZ ULLA” TEAM
medRxiv 2020.05.15.20084293; doi: https://doi.org/10.1101/2020.05.15.20084293

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (164)
  • Allergy and Immunology (417)
  • Anesthesia (93)
  • Cardiovascular Medicine (867)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (398)
  • Epidemiology (8597)
  • Forensic Medicine (4)
  • Gastroenterology (391)
  • Genetic and Genomic Medicine (1775)
  • Geriatric Medicine (170)
  • Health Economics (376)
  • Health Informatics (1252)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (198)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10355)
  • Intensive Care and Critical Care Medicine (554)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (934)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (256)
  • Pediatrics (541)
  • Pharmacology and Therapeutics (257)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1788)
  • Public and Global Health (3877)
  • Radiology and Imaging (629)
  • Rehabilitation Medicine and Physical Therapy (324)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (171)
  • Sports Medicine (159)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)